This report on global Irritable Bowel Syndrome with Constipation (IBS-C) drugs market evaluates the current market scenario and predicts future market trends for the commercialized and pipeline drugs for IBS-C treatment. IBS is among the most commonly prevalent gastrointestinal diseases for which the exact cause is not determined. However, the recent developments in research on this issue have led to the introduction of several novel disease treatment and management solutions.
For the purpose if this study the global irritable bowel syndrome drugs market is studied for three major segmentations namely, drug types, prescription type, and geography. The various drugs markets studies in the IBS-C market include Lubiprostone, Linaclotide, Stimulant Laxatives (Bisacodyl & Senna), Osmotic Laxatives (Lactulose & Polyethylene Glycol) and others. This segmentation studies the market size and forecast of the mentioned drug types for the period 2014 to 2022. The CAGR of the segmentation is provided for the period 2016 – 2022 while considering 2015 as the base year.
In terms of prescription-type, the global IBS-C market segments the drugs market as prescribed drugs and over the counter drugs market. The prescribed drugs market is further studied for prescribed generic and prescribed branded drugs markets. Similar to segmentation by drug types, this segmentation demonstrated the respective market sizes for the period 2014 to 2022, with CAGRs for the period 2016 to 2022.
In terms of geographic distribution, North America, Europe, Asia Pacific and Rest of the World cumulatively make the global IBS-C drugs market. These regional markets are further studied for the key countries that either take a large market share in each respective region or determine the major regional market trends. IBS-C market by geography presents the market size and forecast for each regional market and component countries for the period 2014 to 2022 with the corresponding CAGRs for the period 2016 to 2022. Furthermore, this study also exclusively studies the IBS-C market exclusively for the United States with further cross-sectional market size and forecast by drug type and prescription type.
In addition, to presenting the market size and forecast for the above segmentations, this report studies the market dynamics, market investment propositions, competition assessment and drug profiles in the IBS-C market. This report concludes with profiles of key drug manufacturers active in the IBS-C drugs market.
Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Global IBS-C Drugs Market Analysis
3.1 IBS-C Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
22.214.171.124 Adverse effects on health of various dietary habits
126.96.36.199 Strong clinical pipeline with several first-in-class molecules
188.8.131.52 Effective drugs available in the market
184.108.40.206 Strict FDA regulations
220.127.116.11 High level of ignorance among the patients
18.104.22.168 Emerging APAC Market
22.214.171.124 High Unmet needs
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key IBS Drugs Manufacturers
Chapter 4 Global IBS-C Drugs Market, by Drug Type
4.4 Stimulant Laxatives
4.5 Osmotic Laxatives
4.5.2 Polyethylene Glycol
4.6 Others (Psyllium) – Qualitative Information
4.7 Pipeline Drug Analysis: Plecanatide (Year of Launch to 2022 ($ Million))
Chapter 5 Global IBS-C Drugs Market by Prescription Type
5.2 Prescribed Drugs
5.3 Over the Counter Drugs
Chapter 6 Global OIC Drugs Market, by Geography
6.1 Global IBS-C Drugs Market, by Geography, 2014-2022 (USD Mn)
6.2 North America
6.3.3 Rest of the Europe
6.4 Asia Pacific
6.4.3 Rest of Asia Pacific (APAC)
6.5 Rest of the World (ROW)
6.5.1 Middle East and Africa
6.5.2 Latin America
6.5.3 Rest of the ROW
Chapter 7 Company Profiles
7.1 Catalent Pharmaceuticals Solutions
7.1.2 Catalent Pharma Solutions product portfolio
7.1.3 SCOT Analysis
7.2.2 Nestle products portfolio
7.2.3 SCOT Analysis
7.3 Abbot Laboratories
7.3.2 Abbott Laboratory product portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals
7.4.2 Synergy Pharmaceuticals products portfolio
7.4.3 SCOT Analysis
7.5 Sucampo Pharmaceuticals
7.5.2 Sucampo Pharmaceuticals product portfolio
7.5.3 SCOT Analysis
7.6.2 Novartis Products Portfolio
7.6.3 SCOT Analysis
7.7 Astellas Pharmaceuticals
7.7.2 Astellas Pharmaceuticals Product Portfolio
7.7.3 SCOT Analysis
List of Tables
TABLE 1 Global IBS-C drug market by geography 2014-2022 (USD Mn)
TABLE 2 Prominent IBS Treatment Drugs
TABLE 3 IBS Drugs List
TABLE 4 Global OIC drug market by drug type, 2014-2022 (USD Mn)
TABLE 5 Product Profile (Lubiprostone)
TABLE 6 Linaclotide market by region, 2014-2022 (USD Mn)
TABLE 7 Product Profile: Linaclotide
TABLE 8 Global Stimulant laxatives market by region, 2014-2022 (USD Mn)
TABLE 9 IBS Bisacodyl market by region, 2014-2022 (USD Mn)
TABLE 10 Product Profile: Bisacodyl
TABLE 11 IBS Senna market by region, 2014-2022 USD Mn)
TABLE 12 IBS Senna market by region, 2014-2022 USD Mn)
TABLE 13 Global Lactulose market by region, 2014-2022 (USD Mn)
TABLE 14 Product Profile: Lactulose
TABLE 15 Global Polyethylene Glycol market by region, 2014-2022 (USD Mn)
TABLE 16 Product Profile: Polyethylene Glycol
TABLE 17 IBS Professional Reference Statistics
TABLE 18 Product Profile: Plecanatide
TABLE 19 Global Prescribed IBS-C Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
TABLE 20 Global Prescribed Branded IBS-C Drugs Market, by Geography, 2014-2022 (USD Mn)
TABLE 21 Global Prescribed Generic IBS-C Drugs Market, by Geography, 2014-2022 (USD Mn)
TABLE 22 Global Over the Counter IBS-C Drugs Market, by Geography, 2014-2022 (USD Mn)
TABLE 23 Global IBS-C Drugs Market, by Geography, 2014-2022 (USD Mn)
TABLE 24 Global IBS-C Drugs Market, by Geography, 2014-2022 (USD Mn)
TABLE 25 US IBS-C Drugs Market, by drug type, 2014-2022 (USD Mn)
TABLE 26 Europe IBS-C Drugs Market, by Country, 2014-2022 (USD Mn)
List of Figures
FIG. 1 Global IBS-C drugs market 2014-2022 (USD Mn)
FIG. 2 Global IBS-C Drugs Market, by Prescription Type, 2014 (%)
FIG. 3 IBS-C Prevalence Statistics, 2014 (%)
FIG. 4 Diets Responsible for IBS
FIG. 5 Percentage of Persons Aged 12 and Over with Depression by Age and Sex, US, 2009-2012
FIG. 6 Drugs For Irritable Bowel Syndrome Constipation
FIG. 7 Lifestyle and Home Remedies for IBS
FIG. 8 Drugs Pulled Off from The Market
FIG. 9 IBS Professional Reference Statistics
FIG. 10 Population of Asia by age group in various sub region, July 2013
FIG. 11 Global Lubiprostone Market, by Region, 2014-2022 (USD Mn)
FIG. 12 Pipeline Drug Analysis: Plecanatide (Year of Launch to 2022 (US$ Mn))
FIG. 13 U.S. IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 14 U.S. Prescribed IBS-C Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
FIG. 15 Canada IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 16 U.K. IBS-C Drugs Market, 2014-2022 (%)
FIG. 17 Germany IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 18 Rest of Europe IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 19 Asia Pacific OIC Drugs Market, by Country, 2014-2022 (USD Mn)
FIG. 20 China IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 21 Japan IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 22 APAC IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 23 RoW IBS-C Drugs Market, by Region, 2014-2022 (USD Mn)
FIG. 24 Middle East and Africa OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 25 Latin America IBS-C Drugs Market, 2014-2022 (USD Mn)
FIG. 26 Rest of RoW IBS-C Drugs Market, 2014-2022 (USD Mn)
Irritable Bowel Syndrome with Constipation (IBS-C) drugs are widely adopted across the world, particularly in the regions where the prevalence of the condition is higher. Lubiprostone, Linaclotide, stimulant laxatives (bisacodyl and senna), osmotic laxatives (lactulose and polyethylene glycol) are the major drugs used for IBS-C treatment.
Lubiprostone is an Irritable Bowel Syndrome drug that relieves stomach pain, bloating, and straining and produce softer and more frequent bowel movements in patients suffering from IBS- constipation. IBS creates a difficult or infrequent passage of stool; lubiprostone enables to provide relief for such conditions. It is also used to treat IBS-C which causes stomach pain or cramps, bloating, and infrequent or difficult passage of stool in women who are at least 18 years of age. The demand for lubiprostone is observed to be highest in North America followed by Asia Pacific (in terms of growth rate). Linaclotide enables to significantly relieve constipation by supporting bowel movements occur more often. However, this drug is not tested on pregnant women and it is not approved for use in those age 17 years and younger. The most common side effect of Linzess (linaclotide) is diarrhea and nausea. The key market players such as Sucampo AG, Actavis, Cardinal Health, Catalent Pharma Solutions, and Synergy Pharmaceuticals are expected to contribute significantly in the IBS market during the forecasted period.
For the purpose of this study, the global Irritable Bowel Syndrome with Constipation (IBS-C) Drugs market is categorized into:
In North America, CI and IBS are the two most common functional gastrointestinal disorders. As of 2014, the conditions affect more than 30 Mn individuals. IBS is common among people but often goes undiagnosed until severe. However, reporting of IBS is higher in developed markets. The perpetually growing prevalence rate of the condition has led to voluntary reporting from patients, in North America and Europe.
IBS-C drugs market in Europe has a wide scope as the region has a substantial prevalence of IBS. Amitiza and Linzess are the two most popular drugs offered in Europe market. Also a novel option: Linaclotide is already available in the European market under the brand name Constella. However, limited treatment availability in lesser developed markets and poorly tapped market opportunities in the regions where the need is significant and additional complications from different lifestyle related disorders are some of the factors that hold back the growth of IBS-C drugs market.
Based on the prescription type, the global irritable bowel syndrome with constipation drugs market is segmented into prescription and OTC drugs market. Furthermore, the prescribed IBS-C drugs market is further studied for generic and branded OIC drugs.
Prescription drugs are case specific and have a potential scope in developed nations. IBS prevalence in North America and Europe is higher as against other regions of the world, this phenomenon coupled with higher awareness among physicians and the patient population will lead to greater number of prescriptions of IBS-C drugs in the regions. The most common prescribed drugs in this category include Lubiprostone, bisacodyl and others.
Branded IBS drugs are more adopted in developed economies such as the US, the UK, Germany, France, Spain and Canada. Most of the patients take these drugs for relief from constipation and the drugs enable them for smooth stool under doctor’s supervision. However, there are various side effects and consequences that may follow after taking the medications.
North America has the highest contribution in IBS drug market by generic drugs market followed by Europe. Almost 50% of the US population has one or the other type of constipation problems. There is a huge demand for generic and over the counter drugs in US, UK, France, Spain, Germany, China, India and Indonesia. Lubiprostone, Naloxegol, methylnaltrexone are some common generic drugs which are adopted across the globe. FDA approval is driving the market, for example, the drug Naldemedine, Alvimopan, Dolcanatide are already in the last phase of the clinical trial and expected to hit the market in near future.
Irritable bowel syndrome (IBS) is defined as persistent abdominal discomfort and pain occurring with changed bowel habits. This condition is classified into 3 types based on the prevalent bowel habits: IBS-constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed presentations (IBS-M). It is among the most common gastrointestinal disorders with a worldwide prevalence of approximately 11%. As of 2014, more than 30 million individuals older than age 19 suffered from IBS across key national markets namely the US, the US, France, Italy, Germany, Japan and Spain.
Although not classified as life-threatening, IBS can seriously affect the overall quality of life and is a major contributor to visits to primary care physicians in the developed markets. Pathogenesis of the disease remains unclear; however, some progress on the issue have been witnessed in the recent years. Due to the associated costs and socioeconomic burden, IBS has received considerable focus for discovering effective treatments. The economic outcomes of IBS management are significant contributed by the direct medical costs and the impending burden on time and productivity management.
The IBS market is observed to be underpenetrated and hence is deemed attractive for pharmaceutical manufacturers in the GI drugs market. A majority of IBS patients are women and one third IBS patients experience constipation as a primary syndrome. Awareness about the attractiveness of the market potential and growing understanding of the disease pathophysiology renders growth potential and further evolution in lines with the phenomenal growth of cardiac diseases and GERD markets in the past decades.
Amitiza (Lubiprostone) received approval for IBS-C in the US in 2008. It is indicated exclusively for women with IBS-C with the drug to be taken twice daily. Amitiza is available in 5 EU countries (the UK, Germany, Spain, Italy and France) and Japan, yet not indicated for IBS. Linzess (linaclotide) has been the first drug approved for treatment of IBS-C both in men and women. Both Amitiza and Linzess are second line treatments after no response to laxatives and antispasmodics.
Linzess is less covered by medical reimbursement in the US as against Amitiza, majorly due to its later commercialization. Thought the pricing os the drug is lower than Amitiza, its market size is expected to stay below that of Amitiza. Through indirect comparison, it is indicated that though Linzess has more effectiveness than Amitiza, the risk of diarrhea contributes to its lesser demand in the market.